1. Home
  2. ORGN vs BCAB Comparison

ORGN vs BCAB Comparison

Compare ORGN & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Origin Materials Inc.

ORGN

Origin Materials Inc.

HOLD

Current Price

$0.94

Market Cap

7.5M

Sector

Industrials

ML Signal

HOLD

Logo BioAtla Inc.

BCAB

BioAtla Inc.

HOLD

Current Price

$3.80

Market Cap

6.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ORGN
BCAB
Founded
2008
2007
Country
United States
United States
Employees
91
N/A
Industry
Major Chemicals
Medicinal Chemicals and Botanical Products
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.5M
6.4M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
ORGN
BCAB
Price
$0.94
$3.80
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
107.3K
45.3K
Earning Date
05-14-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
29.86
EPS
N/A
N/A
Revenue
N/A
$300,000.00
Revenue This Year
$503.74
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.10
$0.12
52 Week High
$4.11
$6.52

Technical Indicators

Market Signals
Indicator
ORGN
BCAB
Relative Strength Index (RSI) 26.04 51.59
Support Level $0.47 $3.19
Resistance Level $2.33 $5.18
Average True Range (ATR) 0.09 0.36
MACD -0.02 0.02
Stochastic Oscillator 11.68 57.28

Price Performance

Historical Comparison
ORGN
BCAB

About ORGN Origin Materials Inc.

Origin Materials Inc is a technology company with a mission to enable the world's transition to sustainable materials. The platform turns the carbon found in biomass into useful materials, while eliminating the need for fossil resources and capturing carbon in the process. Its products include PET circular caps and closures, Para-xylene, carbon black, Levulinic acid, among others, by using materials like food and beverage packaging, clothing, textiles, plastics, car parts, carpeting, tires, adhesives, soil amendments, and fuels.

About BCAB BioAtla Inc.

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.

Share on Social Networks: